Bellicum Pharmaceuticals ^{Priced, Nasdaq: BLCM}

Early-stage biotech developing controllable cancer immunotherapies.

Industry: Health Care

First Day Return: +25.7%

BLCM

Early-stage biotech developing controllable cancer immunotherapies.

IPO News for Bellicum Pharmaceuticals

US IPO Weekly Recap: Record 2014 IPO market finishes with a $2 billion cancer biotech 12/19/14
Bellicum Pharmaceuticals prices upsized IPO at $19, above the range 12/18/14
Week ahead: The 2014 IPO market's final round with 6 IPOs planned for the week of Dec 15 12/15/14

IPO Data
IPO Date	12/17/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$140
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Headquarters	Houston, TX, United States
Founded	2004
Employees at IPO	30
Website www.bellicum.com

IPO News for Bellicum Pharmaceuticals

Bellicum Pharmaceuticals (BLCM) Performance